Leerink Partners Upgrades Replimune Group to Outperform, Raises Price Target to $17

Benzinga Newsdesk www.benzinga.com Positive 94.1%

Neg 0% Neu 0% Pos 94.1%

Leerink Partners analyst Jonathan Chang upgrades Replimune Group (NASDAQ:REPL) from Market Perform to Outperform and raises the price target from $11 to $17.